Avalon GloboCare Corp. (ALBT)
- Previous Close
0.2755 - Open
0.2909 - Bid --
- Ask --
- Day's Range
0.2599 - 0.2909 - 52 Week Range
0.2500 - 2.4190 - Volume
3,095 - Avg. Volume
175,949 - Market Cap (intraday)
3.029M - Beta (5Y Monthly) 0.27
- PE Ratio (TTM)
-- - EPS (TTM)
-1.5900 - Earnings Date May 20, 2024 - May 24, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.
www.avalon-globocare.comRecent News: ALBT
Performance Overview: ALBT
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALBT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALBT
Valuation Measures
Market Cap
3.03M
Enterprise Value
31.25M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.29
Price/Book (mrq)
--
Enterprise Value/Revenue
24.89
Enterprise Value/EBITDA
-2.08
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-48.88%
Return on Equity (ttm)
-180.35%
Revenue (ttm)
-7.33M
Net Income Avi to Common (ttm)
-16.71M
Diluted EPS (ttm)
-1.5900
Balance Sheet and Cash Flow
Total Cash (mrq)
285.4k
Total Debt/Equity (mrq)
115.43%
Levered Free Cash Flow (ttm)
-7.69M